BioXcel Therapeutics is trading at $0.12 (-10.51%) after continued selling following its August 27, 2026 Chapter 11 filing and proposed asset sale.
- The restructuring includes up to $19 million in debtor-in-possession financing and a proposed $57.5 million Teva asset purchase agreement.
- Shares have fallen sharply across recent sessions despite broader biotech strength, indicating company-specific distress remains dominant.